Abstract
The European Joint Programme on Neurodegenerative Disease Research (JPND) committed to our SRA-NED Working Group (http://www.sra-ned.org/) the survey of the international community for identifying (1) current barriers for a harmonized use of MRI/PET/EEG biomarkers of neurodegenerative diseases and (2) community driven solutions to overcome them. A 10-minute survey (both multiple choice and open questions) was developed to gather information from relevant communities (neuroimaging consortia, industry, and more than 30 international researcher & medical associations). For each of the neuroimaging modalities the survey evaluated high-level barriers to participate in multicentric studies, biomarkers to be prioritized and current challenges for modality-specific harmonization issues. Furthermore, suggestions were collected for overcoming these barriers. 459 participants completed the survey between February 1 and March 31, 2017 (MRI 53.6%, EEG 30.3%, and PETSPECT 16.1%). Participants represented a strong multidisciplinary community, dominated by research and academia while also including industry and clinical settings (Europe 75%, North and South America 20%, and Asia, Oceania and Africa 5%). In all modalities (MRI/PET/EEG), more than 60% of the participants reported significant difficulties for including neuroimaging markers in multicentric clinical studies, and several barriers were specified for each neuroimaging modality. Survey participants converged to specific requests about support needs for a more productive use of those MRI/PET/EEG biomarkers. The results allowed the drawing of concrete suggestions for potential solutions, inspiring a roadmap for future investments of international sponsors for clinical trials in neurodegenerative diseases. To our knowledge, the SRA-NED survey represents the largest survey of the clinical neuroimaging community in the field of neurodegenerative diseases. The results provided make way for a strategic research agenda of future investments to exploit the potential of the MRI/PET/EEG biomarkers in large multi-centric studies in neurodegenerative diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
